β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure

Autor: G. Ambrosio, M. D. Flather, M. Böhm, A. J.S. Coats, L. Tavazzi, D. J. van Veldhuisen, M. G. Conti, G. Spinucci, F. Mascagni, A. Murrone, A. Cohen-Solal
Jazyk: ruština
Rok vydání: 2011
Předmět:
Zdroj: Кардиоваскулярная терапия и профилактика, Vol 10, Iss 4, Pp 69-76 (2011)
Druh dokumentu: article
ISSN: 1728-8800
2619-0125
DOI: 10.15829/1728-8800-2011-4-69-76
Popis: Aim. This subanalysis of the Study of the Effects of Nebivolol Intervention on Outcomes and Hospitalisation in Seniors with Heart Failure (SENIORS) investigates whether treatment with nebivolol, a β-blocker with nitric oxide-releasing properties, can provide additional benefits besides its effects on heart failure (HF), by reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. Material and methods. A double-blind, randomised, placebo-controlled, multicentre trial of nebivolol in 2128 elderly patients. For this analysis, data were extracted for 2128 elderly (≥70 years) HF patients in whom coronary artery disease (CAD) was the underlying aetiology (68,2 %; 717 placebo-treated patients and 735 assigned to nebivolol). The main endpoint was the composite of cardiac ischaemic events at 2 year follow-up: death/hospitalisation for myocardial infarction, unstable angina or sudden death, as originally identified in the case report form. Results. At follow-up, nebivolol treatment was associated with a one-third reduction in the risk of ischaemic events, the composite endpoint occurring in 15,9 % of placebo and 10,7 % of nebivolol-treated patients (HR 0,68; 95 % CI 0,51 to 0,90; p=0,008). This effect was independent of age, gender and ejection fraction. No difference in this composite endpoint was observed in the subgroup of patients of non-ischaemic aetiology. Conclusion. Nebivolol was effective in reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. The prevention of ischaemic events can be an additional beneficial effect of β-blockade in HF patients with underlying CAD.
Databáze: Directory of Open Access Journals
Externí odkaz: